What it means: Participants received either a low, medium or high dose of the vaccine. Those who in all three groups who received both shots eventually produced “high levels of neutralizing antibody activity” that may keep https://bt-hypnotise.com/ at bay, the scientists reported. The antibody levels were similar to those seen in people who recovered from coronavirus infections.
But wait: The development of the antibodies is not direct proof that the vaccine works. Determining that will require a final, Phase III clinical trial.
What’s next: Researchers began enrolling participants in a Phase II trial in late May to further study the vaccine’s safety and its ability to produce an immune response.
Moderna plans to start a Phase III trial on July 27 to determine whether the vaccine can prevent coronavirus infection. That trial — conducted with help from NIAID and the federal government’s Operation Warp Speed initiative — will eventually enroll 30,000 people.